204 research outputs found
Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA). However, three-year mortality remains over 30%. Stimulation of counter-regulatory systems in addition to neurohormonal blockade constitutes a new paradigm, termed neurohormonal modulation. Sacubitril/valsartan is the first element of this new strategy. PARADIGM-HF was the largest randomized clinical trial conducted in HFrEF. It included 8442 patients and compared the efficacy and safety of sacubitril/valsartan versus enalapril. The primary endpoint was the composite of cardiovascular mortality and hospitalization due to HF, which occurred in 914 (21.8%) patients receiving sacubitril/valsartan and in 1117 (26.5%) patients receiving enalapril (HR 0.8, 95% CI 0.73-0.87, p=0.0000002; NNT 21). Sacubitril/valsartan reduced both primary endpoint components, as well as sudden cardiac death, death due to worsening HF, and death from all causes. Patients on sacubitril/valsartan reported less frequent deterioration of HF and of quality of life, and discontinued study medication less frequently because of an adverse event. PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril, with a 20% greater impact on cardiovascular mortality compared to ACEIs. Accordingly, in 2016, the European (ESC) and American (ACC/AHA/HFSA) cardiology societies simultaneously issued a class I recommendation for the replacement of ACEIs by sacubitril/valsartan in patients resembling PARADIGM-HF trial participants.info:eu-repo/semantics/publishedVersio
A 1000-year-old mystery solved: Unlocking the molecular structure for the medieval blue from Chrozophora tinctoria, also known as folium
The molecular structure of the medieval watercolor known as folium has finally been solved in the 21st century. The interdisciplinary approach taken was the key to producing extracts that had been prepared following medieval instructions, and shows the blue/purple chromophore as the major dye in Chrozophora tinctoria fruits (shell). A multi-analytical characterization of its structure was made using HPLC-DAD-MS, GC-MS, NMR (1H, 13C, COSY, HSQC, HMBC, INADEQUATE), and computational studies. The results demonstrate that the blue compound corresponds to 6'-hydroxy-4,4'-dimethoxy-1,1'-dimethyl-5'-{[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-[3,3'-bipyridine]-2,2',5,6(1H,1'H)-tetraone, a hermidin derivative, which we named chrozophoridin. Experimental data and computational modeling studies show that this mono-glycosylated dimer is represented by two stable isomers (atropisomers). This is an indispensable piece of knowledge for the characterization of this medieval dye in works of art such as medieval manuscript illuminations and for testing its stability and contributes to the preservation of our cultural heritage.info:eu-repo/semantics/publishedVersio
Added value of lymphocyte subpopulations in the classification of Sjögren's syndrome
Sjögren's Syndrome (SjS) is a chronic systemic immune-mediated inflammatory disease characterized by lymphocytic infiltration and consequent lesion of exocrine glands. SjS diagnosis and classification remains a challenge, especially at SjS onset, when patients may have milder phenotypes of the disease or uncommon presentations. New biomarkers are needed for the classification of SjS, thus, we aimed to evaluate the added-value of lymphocyte subpopulations in discriminating SjS and non-Sjögren Sicca patients. Lymphocyte subsets from 62 SjS and 63 Sicca patients were characterized by flow cytometry. The 2002 AECG and the 2016 ACR/EULAR SjS classification criteria were compared with clinical diagnosis. The added discriminative ability of joining lymphocytic populations to classification criteria was assessed by the area under the Receiver-Operating-Characteristic Curve (AUC). Considering clinical diagnosis as the gold-standard, we obtained an AUC = 0.952 (95% CI: 0.916-0.989) for AECG and an AUC = 0.921 (95% CI: 0.875-0.966) for ACR/EULAR criteria. Adding Tfh and Bm1 subsets to AECG criteria, performance increased, attaining an AUC = 0.985 (95% CI: 0.968-1.000) (p = 0.021). Th1/Breg-like CD24hiCD27+ and switched-memory B-cells maximized the AUC of ACR/EULAR criteria to 0.953 (95% CI: 0.916-0.990) (p = 0.043). Our exploratory study supports the potential use of lymphocyte subpopulations, such as unswitched memory B cells, to improve the performance of classification criteria, since their discriminative ability increases when specific subsets are added to the criteria.info:eu-repo/semantics/publishedVersio
o novo paradigma do tratamento farmacológico da Insuficiência Cardíaca
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA). However, three-year mortality remains over 30%. Stimulation of counter-regulatory systems in addition to neurohormonal blockade constitutes a new paradigm, termed neurohormonal modulation. Sacubitril/valsartan is the first element of this new strategy. PARADIGM-HF was the largest randomized clinical trial conducted in HFrEF. It included 8442 patients and compared the efficacy and safety of sacubitril/valsartan versus enalapril. The primary endpoint was the composite of cardiovascular mortality and hospitalization due to HF, which occurred in 914 (21.8%) patients receiving sacubitril/valsartan and in 1117 (26.5%) patients receiving enalapril (HR 0.8, 95% CI 0.73-0.87, p=0.0000002; NNT 21). Sacubitril/valsartan reduced both primary endpoint components, as well as sudden cardiac death, death due to worsening HF, and death from all causes. Patients on sacubitril/valsartan reported less frequent deterioration of HF and of quality of life, and discontinued study medication less frequently because of an adverse event. PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril, with a 20% greater impact on cardiovascular mortality compared to ACEIs. Accordingly, in 2016, the European (ESC) and American (ACC/AHA/HFSA) cardiology societies simultaneously issued a class I recommendation for the replacement of ACEIs by sacubitril/valsartan in patients resembling PARADIGM-HF trial participants.publishersversionpublishe
Signal yields, energy resolution, and recombination fluctuations in liquid xenon
This work presents an analysis of monoenergetic electronic recoil peaks in
the dark-matter-search and calibration data from the first underground science
run of the Large Underground Xenon (LUX) detector. Liquid xenon charge and
light yields for electronic recoil energies between 5.2 and 661.7 keV are
measured, as well as the energy resolution for the LUX detector at those same
energies. Additionally, there is an interpretation of existing measurements and
descriptions of electron-ion recombination fluctuations in liquid xenon as
limiting cases of a more general liquid xenon re- combination fluctuation
model. Measurements of the standard deviation of these fluctuations at
monoenergetic electronic recoil peaks exhibit a linear dependence on the number
of ions for energy deposits up to 661.7 keV, consistent with previous LUX
measurements between 2-16 keV with H. We highlight similarities in liquid
xenon recombination for electronic and nuclear recoils with a comparison of
recombination fluctuations measured with low-energy calibration data.Comment: 11 pages, 12 figures, 3 table
Identification of Radiopure Titanium for the LZ Dark Matter Experiment and Future Rare Event Searches
The LUX-ZEPLIN (LZ) experiment will search for dark matter particle
interactions with a detector containing a total of 10 tonnes of liquid xenon
within a double-vessel cryostat. The large mass and proximity of the cryostat
to the active detector volume demand the use of material with extremely low
intrinsic radioactivity. We report on the radioassay campaign conducted to
identify suitable metals, the determination of factors limiting radiopure
production, and the selection of titanium for construction of the LZ cryostat
and other detector components. This titanium has been measured with activities
of U~1.6~mBq/kg, U~0.09~mBq/kg,
Th~~mBq/kg, Th~~mBq/kg, K~0.54~mBq/kg, and Co~0.02~mBq/kg (68\% CL).
Such low intrinsic activities, which are some of the lowest ever reported for
titanium, enable its use for future dark matter and other rare event searches.
Monte Carlo simulations have been performed to assess the expected background
contribution from the LZ cryostat with this radioactivity. In 1,000 days of
WIMP search exposure of a 5.6-tonne fiducial mass, the cryostat will contribute
only a mean background of (stat)(sys) counts.Comment: 13 pages, 3 figures, accepted for publication in Astroparticle
Physic
- …